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ABSTRACT 
Negative regulation of B cell activation by cognate immune complexes plays an 
important homeostatic role in suppressing B cell hyperactivity and preventing 
consequent autoimmunity. Immune complexes co-ligate the BCR and FcγRIIB 
resulting in both growth arrest and apoptosis. We now show that such apoptotic 
signalling involves induction and activation of p53 and its target genes, the pro-
apoptotic Bcl-2 family members, Bad and Bid, as well as nuclear export of p53. 
Collectively, these events result in destabilisation of the mitochondrial and 
lysosomal compartments with consequent activation and interplay of executioner 
caspases and endosomal-derived proteases. In addition, the upregulation of Fas 
and FasL with consequent activation of caspase 8-dependent death receptor 
signalling is required to facilitate efficient apoptosis of B cells. Consistent with 
this role for Fas death receptor signalling, apoptosis resulting from co-ligation of 
the BCR and FcγRIIB is defective in B cells from Fas-deficient MRL/MpJ-Faslpr 
mice. As these mice develop spontaneous, immune complex-driven lupus-like 
glomerulonephritis, targeting this FcγRIIB-mediated apoptotic pathway may 
therefore have novel therapeutic implications for systemic autoimmune disease. 
Keywords: B lymphocytes, FcγRIIB, apoptosis, caspases, Fas 
 
3 
1. INTRODUCTION 
B-lymphocytes are the principal mediators of the humoral (antibody) immune 
response: recognition of antigen (Ag) by the B cell Receptor (BCR) induces the 
clonal expansion and differentiation of B cells into antibody (Ab)-producing 
plasma cells [1]. Negative feedback inhibition of such responses by cognate 
IgG-containing immune complexes [2-6] is a result of co-ligation of the BCR with 
the low affinity Fcγ receptor, FcγRIIB, promoting the induction of growth arrest in 
the G1 phase of the cell cycle and consequent commitment of the B cells to 
apoptosis [7, 8]. In addition to such homeostatic negative feedback inhibition of 
ongoing B cell responses, ligation of FcγRIIB by non-cognate immune 
complexes can induce B cell anergy and/or apoptosis and hence, FcγRIIB 
signalling acts to suppress B cell activation and potential autoimmunity [8, 9]. 
The precise mechanisms underlying apoptosis resulting from co-ligation 
of the BCR with FcγRIIB have yet to be delineated but we and others have 
previously reported recruitment of negative elements (eg SHIP, SHP, DOK, 
PTEN and PAC-1) that antagonise BCR signalling [10-13] as well as disruption 
of the mitochondrial membrane potential (MMP) [14], the loss of which is 
considered to be the so called ‘point of no return’, after which cells irreversibly 
engage the ‘intrinsic’ or mitochondrial apoptosis programme [15]. We now show 
that such FcγRIIB-driven apoptosis is mediated by both mitochondrial- and 
lysosomal-effector mechanisms and by upregulation of Fas and consequent 
coupling to caspase 8-dependent death receptor signalling. 
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2. MATERIALS AND METHODS  
2.1. Animals 
MRL/MpJ-Faslpr and the parental strain, MRL/MpJ were purchased from Harlan 
Laboratories (Oxon, UK) and then maintained with “in house” bred BALB/c mice at the 
Central Research Facility, University of Glasgow in accordance with UK Home Office 
Licence guidelines. 
2.2. Antibodies, inhibitors and cell culture reagents 
Cell culture reagents were purchased from Invitrogen Life Technologies (Paisley, UK) 
except for foetal bovine serum (FBS), which was obtained from Lonza (Lonza 
Biologicals, Cambridge UK). B cells were stimulated by F(ab’)2 fragments of goat-anti-
mouse IgM antibodies at 50 µg/ml to ligate the BCR and intact rabbit anti-mouse anti-
IgM  antibodies at 75 µg/ml  to co-ligate the BCR and FcγRIIB (Jackson 
Immunoresearch Laboratories, Stratech Scientific Ltd; Beds., UK) except where the 
following antibodies were indicated to ligate the BCR and FcγRIIB: monoclonal rat anti-
mouse IgM (B7.6) at 50 µg/ml (BCR), monoclonal rat anti-mouse FcγRIIB (2.4G2) at 50 
µg/ml and donkey anti-rat IgG (Jackson Immunoresearch Laboratories) at 75 µg/ml to 
cross-link the B7.6 and 2.4G2 antibodies [10]. Additional antibodies were: anti-BAD 
(C20), anti-Cathepsin-B (C-19), anti-GAPDH and anti-β-actin (Santa Cruz 
Biotechnology Inc. Heidelberg, Germany); anti-full length and anti-cleaved caspase 8, 
anti-phosphoSer15-p53, anti-p53 (1C12), anti-BID, (Cell Signaling Technology, 
Danvers, MA); anti-Fas (Clone 13, BD Biosciences, Oxford, UK or rabbit polyclonal 
Santa Cruz), anti-FASL (Clone 33, BD Biosciences; Armenian hamster anti-FasL (anti-
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CD178) IgG antibody and isotype control, BioLegend, Cambridge Bioscience, 
Cambridge UK; ) and anti-p53 (Calbiochem, Merck, Middlesex UK).  
Inhibitors of caspase 8 (z-IETD-FMK), capase 9 (z-LEHD-FMK), caspase 2  (z-
VDVAD-FMK), caspase 3 (z-DEVD-FMK), cathepsin B (EST) and calpain (inhibitor V) 
were purchased from Calbiochem (Merck) [16-18]. The pan-caspase inhibitor (Q-VD-
OPhe [19]) was obtained from Imgenex Corp (Cambridge Bioscience) while E64d, 
Pepstatin A and Microcystin were from Enzo Life Sciences (Exeter UK). 
2.3. DNA Synthesis ([3H]-thymidine uptake) assay  
Murine B cells (>95% B220+) were purified from BALB/c (>9 weeks) spleens using the 
CD43-magnetic bead negative-selection method according to the manufacturer’s 
instructions (Miltenyi Biotec, Surrey UK). B cells (2 x 105 cells/well) were stimulated as 
indicated (in triplicate) in RPMI-1640 medium containing 5% FBS, 100 U/ml penicillin, 
100 µg/ml streptomycin, 2 mM glutamine and 50 µM 2-mercapthoethanol,1% (v/v) non-
essential amino acids and 1 mM sodium pyruvate for 48 h at 37oC in 5% (v/v) CO2 
atmosphere and pulsed with 0.5 µCi/well [6-3H]-thymidine (Amersham Pharmacia 
Biotech, GE Healthcare Life Sciences, Bucks., UK) for the last 4 h of culture before 
harvesting using a Betaplate 96-well liquid scintillation counter (Amersham)  
2.4. Flow cytometry 
All data were acquired with a FACSCalibur using CellQuest software (BD Biosciences) 
and analysed by FlowJo software (TreeStar Inc., Ashland, OR) as described previously 
[20, 21]. 
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2.4.1. Phenotypic markers  
Cells (0.5 x 106 cells/sample) were washed with ice-cold PBS containing 1% BSA and 
2mM EDTA, 0.05% sodium azide and incubated with the indicated fluorochrome-
conjugated Abs for 30 min at 4°C. Antibodies used for FACS analysis were anti-Fas, 
purified and FITC-conjugated (Jo2, BD Biosciences), anti-B220-APC (RA3-6B2) and 
anti-CD43-PE (1B11; BioLegend).   
2.4.2. CFSE analysis 
Cells (105 cells/sample) were resuspended in PBS containing 0.1% BSA and loaded 
with 2.5 µM CFSE for 10 min at 37°C. CFSE staining was detected by FACS and 
analysed using FlowJo software to identify the number of cell divisions undergone.  
2.4.3. DNA Content Analysis  
Cells were stained with propidium iodide (PI) solution (0.1% (w/v) sodium (tri) citrate, 
0.1% (v/v) triton-X-100, 50 µg/ml PI, 50 µg/ml RNase A) for 30 min on ice.  
2.4.4. MMP  
Cells were stained with 2.5 µM DiOC6 (Molecular Probes, Invitrogen Life Technologies) 
in PBS containing 0.1% BSA for 30 min at room temperature. The typical biphasic 
profiles enabled gating of cells into high (healthy) or low (apoptotic) MMP. 
2.4.5. LMP  
Lysosomal damage was assessed by acridine orange (1 µg/ml, AO, Sigma) or 
Lysotracker Red DND99 (100 nM, Invitrogen Life Technologies) assays [22, 23] 
following staining for 30 min or 1 h at 37°C in the dark, respectively.  
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2.4.6. Caspase activity 
Cells (106 cells/well) were treated with the indicated stimuli at 37°C/5% CO2 for up to 24 
h before incubation with appropriate FITC-labelled caspase inhibitor (BioVision, 
Cambridge Bioscience) for 45 min.  
2.5. Whole cell lysates and immune complexes 
B cells (107 cells/sample) were lysed by the addition of ice-cold, modified RIPA buffer 
(50 mM Tris, pH 7.4, 150 mM sodium chloride, 2% (v/v) NP-40, 0.25% (w/v) sodium 
deoxycholate, 1 mM EGTA, 10 mM sodium orthovanadate plus 0.5 mM 
phenylmethylsulfonyl fluoride, 10 µg/ml chymostatin, leupeptin, antipapain and 
pepstatin) and solubilised on ice for 30 min. Samples (1 mg/ml) were pre-cleared with 
protein-G-sepharose before being incubated with antibody (1-2 µg/sample) overnight at 
4oC with constant rotation. Protein G-sepharose (10 µl) was then added for 2 h at 4°C 
and immune-complexes harvested by centrifugation (20,000 x g, 30 min, 4°C) followed 
by release from the sepharose beads by boiling in 50 mM Tris pH 6.8, 2% (v/v) 
bromophenol blue, 0.1% SDS and 10% v/v glycerol containing 2.5% 2-ME for 10 min at 
100°C and pelleting of beads.  
2.6. Cytosolic and membrane/organelle fractions 
Membrane/organelle and cytosolic fractions (5-10 x 106 cells/sample) were prepared 
using the ProteoExtract Subcellular Proteome Extraction Kit from Calbiochem. 
Mitochondrial and cytosolic fractions (5x107 cells/sample) were prepared using the 
mitochondrial extraction kit from Active Motif (La Hulpe, Belgium). Nuclear and cytosolic 
fractions were prepared using the ProteoExtract Subcellular Proteome Extraction Kit 
from Calbiochem or in some experiments, using the Active Motif Nuclear Extract kit.  
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2.7. Western Blot Analysis 
Protein (whole cell lysates) or cell equivalents (subcellular fractions) of samples were 
resolved on the XCell SureLock Mini-Cell kit with NuPAGE Novex high-performance 
pre-cast Bis-Tris gels and NuPAGE buffers and reagents (Invitrogen Life Technologies) 
at 200 V for 50 min. Proteins were transferred to nitrocellulose (Amersham) or PVDF 
(Millipore, Watford, UK) and membranes were blocked by incubating for 1 h in 5% non-
fat milk or BSA in TBS/Tween (0.5 M NaCl and 20 mM Tris pH7.5 with 0.1% (v/v) 
Tween-20) at RT. Membranes were incubated with primary antibody diluted in 5% non-
fat milk or BSA in TBS/Tween buffer overnight at 4°C, washed with TBS/Tween and 
incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary 
antibody for 1 h at RT. Membranes were then washed with TBS/Tween and protein 
bands were visualised using the ECL detection system. Quantification of the bands was 
performed using ImageJ software (National Institute of Health). 
2.8. Cytochrome C, TransAM and FACE assays  
Cytochrome C levels in cytosolic and mitochondrial fractions (cell equivalents) were 
measured by ELISA. p53 activity in nuclear extracts (2 µg) was measured using a 
TransAM kit. AKT activity and BAD phosphorylation status (5 x 105 cells/well) were 
measured by FACE assays. All kits were from Active Motif and performed according to 
manufacturer’s instructions.  
2.9. RT-PCR 
Total mRNA was isolated using a RNeasy Mini Kit (Qiagen, Crawley, West Sussex) and 
DNAse I digested RNA transcribed into cDNA using the Superscript II Reverse 
Transcriptase system (Invitrogen Life Technologies) or High Capacity cDNA Reverse 
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Transcription Kit (Applied Biosystems, Life Technologies). FASL Primers were from 
Applied Biosystems (Mm 00438864) and RT-PCR was performed using Eurogentec 
mastermix. The probes contained a reporter (FAM) and quencher (TAMRA) dye and 
PCR reactions were performed in the ABI-prism 7700 Sequence Detector or the 
7900HT Fast Real-Time PCR System (Applied Biosystems) and amplification was 
performed using the following conditions: 2 min at 50°C, 10 min at 95°C, followed by a 
total of 45 two-temperature cycles (15 s at 95°C and 1 min at 60°C).  
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3. Results  
3.1. Apoptosis resulting from co-ligation of the BCR and FcγRIIB can be blocked 
by the pan-caspase inhibitor Q-VD-OPhe   
Co-ligation of the BCR and FcγRIIB (X) inhibits BCR-mediated proliferation (Fig. 1A): 
we, and others, have previously shown [14, 24] that this reflects G0/G1 growth arrest 
(Figs. 1Aii & 1B) and commitment to apoptosis consequent to disruption of the MMP 
and cytochrome C release from mitochondria to the cytosol (Figs. 1B-E). Although 
growth arrest was not reversed by treatment with the pan-caspase inhibitor, Q-VD-
OPhe (Q; Figs. 1Aii & B) the dissipation of MMP, which could be detected within 6-18 h 
following BCR/FcγRIIB co-ligation (Fig. 1D), and apoptosis were suppressed to the 
levels observed in cells treated with the survival stimulus, IL-4 (Figs. 1B-D).  
3.2. Co-ligation of BCR/FcγRIIB activates multiple caspases  
To identify which caspases are involved in transducing apoptosis, we assayed for 
activation of initiator and executioner caspases and found that caspases 3, 8 and 9 
were activated following BCR/FcγRIIB co-ligation as early as 6 h (Figs. 2A-C). Caspase 
2 was also assayed at 18h and found to be active (results not shown). Pre-treatment 
with the pan-caspase inhibitor Q-VD-OPhe reduced the levels of BCR/FcγRIIB-
stimulated caspase activation to those observed with the IL-4 alone, confirming that the 
caspase activation is specific and occurs as a result of BCR/FcγRIIB co-ligation.  
Having ascertained that caspases 2, 3, 8 and 9 are activated upon BCR/FcγRIIB 
co-ligation, we investigated which, if any, of these play a crucial role in the resulting 
apoptotic programme. Although not as effective as the pan-caspase inhibitor, Q-VD-
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OPhe (caspases 1-9 and 12), pre-treatment with the specific caspase 8 inhibitor (Z-
IETD-FMK) suppressed BCR/FcγRIIB-mediated apoptosis to the levels observed in 
cells stimulated with the survival signal, IL-4. Similarly, but to a lesser extent, inhibitors 
of caspase 9 (Z-LEHD-FMK) and caspase 3 (Z-DEVD-FMK), but not that of caspase 2 
(Z-VDVAD-FMK), also provided rescue from apoptosis (Fig. 3A), although the caspase 
3 inhibitor has also been reported to inhibit human caspases 6-8 and 10, albeit at 
higher concentrations [18, 25]. By contrast, none of these selective inhibitors of 
caspases were able to significantly block MMP dissipation (Fig. 3B and results not 
shown), suggesting that caspases 3, 8 and 9 mediated their apoptotic effects 
independently and/or downstream of mitochondrial disruption. Moreover, as with Q-VD-
OPhe, none of the selective caspase inhibitors tested were able to restore BCR-
mediated cell proliferation as assessed by DNA synthesis (Fig. 3C).  
 
3.3. BCR/FcγRIIB co-ligation induces lysosomal destabilisation  
There is increasing evidence that in addition to effector caspases, proteases released 
from the endosomal/lysosomal system are also involved in executing apoptotic 
programmes [26]. Indeed, we have previously shown that Cathepsin B plays a key role 
in mediating BCR-driven apoptosis of the immature B cell lymphoma, WEHI-231 [21] 
and it has been more recently shown that germinal centre (GC) B cells undergo 
apoptosis which involves lysosomal destabilisation indicative of lysosomal membrane 
permeabilisation (LMP) and release of such proteases [27]. BCR/FcγRIIB co-ligation 
was found to cause LMP within 3-6 h (Fig. 4A) as indicated by both the AO and 
lysotracker assays and detection of cleaved Cathepsin B in the cytosolic compartment 
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(Fig. 4B). Consistent with LMP playing a role in transducing apoptosis resulting from 
BCR/FcγRIIB co-ligation, LMP was reduced to the levels observed in the presence of 
the survival signal IL-4 by the pan-caspase inhibitor Q-VD-OPhe (Fig. 4C). Perhaps 
rather surprisingly therefore, BCR/FcγRIIB-mediated apoptosis was not blocked by 
selective inhibitors of the endosomal-derived proteases Cathepsin B and Calpain (EST 
and Calpain Inhibitor, respectively) or the lysosomal protease inhibitors, E64d plus 
Pepstatin A (Fig. 4D). However, the partial rescue afforded by the caspase 9 inhibitor 
was substantially enhanced when the cells were treated with the caspase 9 inhibitor in 
combination with the inhibitors of Cathepsin B plus Calpain but not the inhibitors of 
lysosomal proteases, E64d plus Pepstatin A (Figs. 4D). Similar effects were observed 
when the cells were treated with the caspase 3 inhibitor, in concert with inhibitors of the 
endosomal or lysosomal proteases (data not shown). Although LMP appeared to be an 
earlier event than disruption of MMP, blocking of caspase or endosomal/lysosomal 
protease activity, either alone or in combination, did not prevent MMP dissipation (data 
not shown).  Similarly, LMP was not prevented by treatment with any of the selective 
inhibitors of caspases found to suppress apoptosis, either alone or in combination with 
the inhibitors of endosomal/lysosomal proteases (data not shown).  
3.4. Interplay of p53, Bid and Bad signalling is associated with mitochondrial and 
lysosomal disruption consequent to BCR/FcγRIIB co-ligation  
The tumour suppressor, p53 mediates apoptosis via transcriptional regulation of genes 
such as pro-apoptotic Bcl-2 family members including Bad, Bid and Bax [28-32]. 
Consistent with this, BCR/FcγRIIB signalling upregulates p53 expression, 
phosphorylation and transactivation, relative to that seen in B cells stimulated via the 
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BCR or treated with IL-4 alone (Figs. 5A & B), and results in the upregulation of the 
p53 targets, Bid (Figs. 5C) and Bad (Fig. 5D).  These Bcl-2 family members have been 
implicated in the oligomerisation of Bax resulting in dissipation of the MMP and LMP 
[15, 33].  
In addition to being upregulated following BCR/FcγRIIB signalling, Bid is 
proteolytically cleaved to the truncated tBid product (Fig. 5C) that has been reported to 
translocate to the outer mitochondrial membrane to facilitate Bax/Bak pore formation 
[34, 35] and to the lysosomes to promote release of Cathepsin B [33, 36]. Consistent 
with its protective effects against MMP and LMP, the pan-caspase inhibitor Q-VD-
OPhe inhibits BCR/FcγRIIB-mediated caspase 8 cleavage and tBid generation. By 
contrast, although Bid has been reported to be a caspase 8 target, the caspase 8 
inhibitor (z-IETD-FMK) did not block generation of tBid (Fig. 5C), a finding that is 
consistent with its observed lack of protection against MMP and LMP (Fig. 3B & 4C).  
Akt-mediated hyper-phosphorylation of Bad leads to its sequestration by 14-3-3 
proteins and functional inactivation [29, 37]. Thus, the finding that B cells exhibiting 
higher levels of Bad expression in response to BCR/FcγRIIB crosslinking (Fig. 5D) also 
show reduced Bad phosphorylation and Akt activity (Fig. 6A), compared with those 
stimulated via the BCR, provides support for a role for Bad in destabilising 
mitochondrial and/or lysosomal membranes under such apoptotic conditions.  
Moreover, p53 can act as an inducer of apoptosis independently of its 
transcriptional activity. Thus, it has been shown that p53 can translocate to the 
cytoplasm where it acts, either independently or in concert with Bid [38, 39] or Bad [40], 
on mitochondria and/or lysosomes to induce MMP disruption and/or LMP [33, 38, 40-
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42]. Analysis of the cytosolic and nuclear fractions of B cells following co-ligation of the 
BCR/FcγRIIB revealed p53 to be found in both locations (Fig 6B) suggesting that under 
such apoptosis-inducing conditions, p53 is fulfilling both indirect gene induction and 
direct MMP/LMP-apoptotic functions. Further support for a direct p53-mediated LMP 
mode of action was provided by the finding that FcγRIIB- or BCR/FcγRIIB-, but not BCR, 
signalling resulted in the phosphorylation of p53 on Ser15 prior to onset of LMP (Figs. 
5A & 6C) as this modification has been reported to act as a lysosomal targeting signal 
for p53 where it interacts with the lysosomal-associated apoptosis-inducing protein 
containing the pleckstrin homology and FYVE domains (LAPF) and triggers LMP 
associated with apoptosis [41].  Treatment of the cells with the pan-caspase or caspase 
8 inhibitors did not suppress the cytosolic expression of p53.  
3.5. BCR/FcγRIIB co-ligation modulates Fas/FasL expression and consequent 
death receptor signalling  
Collectively, the above data suggest that caspase 8, Bad, Bid and p53 are major 
players in executing the apoptotic programme initiated by BCR/FcγRIIB co-ligation. As 
these are all targets of death receptor signalling [43] and activated B cells are known to 
express the death receptor, Fas on their surface [44-46], we next investigated whether 
co-ligation of BCR/FcγRIIB co-ligation modulates Fas and/or FasL expression 
rendering them susceptible to Fas/FasL mediated cell death.  
BCR/FcγRIIB co-ligation was indeed found to substantially increase both the 
portion of B cells expressing Fas on their surface and also the levels of Fas expressed 
on the surface of such cells, compared to the levels detected on cells treated with IL-4, 
and this upregulation was caspase 8 independent  (Fig. 7A). These findings were 
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corroborated by the analysis of total Fas protein expression, in the presence and 
absence of the caspase 8 and pan-caspase inhibitors, by Western blot analysis which 
confirmed that the increased expression following BCR/FcγRIIB co-ligation was 
caspase independent (Fig. 7B and results not shown).  
Fas signalling is initiated by FasL-mediated receptor trimerisation which drives 
formation of the Death Inducing Signalling Complex (DISC) and activation of caspase 8 
[47]. Consistent with reports that FasL has also been shown to be expressed by 
activated B cells [44], assessment of the levels of FasL expression by Western blot and 
q-RT-PCR analysis revealed that BCR/FcγRIIB stimulation (Figs. 7Bi-iii) also 
upregulates FasL mRNA and protein expression, relative to that seen following 
crosslinking of the BCR, in a caspase 8 independent manner, presumably to facilitate 
efficient induction of apoptosis via fratricide or suicide of immune complex-regulated B 
cells.  
That Fas/FasL signalling plays a functional role in immune complex-driven 
apoptosis was shown by (a) the ability of anti-FasL blocking antibodies to suppress the 
extent of BCR/FcγRIIB-mediated apoptosis (Fig. 8A) and (b) the dysfunctional 
apoptotic responses of B cells from the MRL/MpJ-Faslpr mouse (7-20 weeks), which do 
not express, or upregulate Fas on their cell surface in response to co-ligation of the 
BCR/FcγRIIB (Fig. 8B). Such naïve, quiescent (CD43-) B cells express the BCR and 
FcγRIIB at levels comparable to those of B cells from Fas+/+ BALB/c mice and these 
receptors are downregulated to a similar degree following BCR/FcγRIIB co-ligation in 
both the Fas-deficient and wild type cells (Fig. 8C & D). However, MRL/Lpr B cells 
displayed reduced apoptosis and growth arrest (inhibition of DNA synthesis) resulting 
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from BCR/FcγRIIB co-ligation relative to cells from the parental MRL/MpJ and BALB/c 
mouse strains (Fig. 9A&B). Importantly, this reduction in apoptosis observed in 
MRL/MpJ-Faslpr B cells did not simply reflect modulation of the kinetics of induction of 
LMP, MMP or sub-diploid status of the cells in response to BCR/FcγRIIB co-ligation 
observed in BALB/c B cells (Fig. 9C), indicating involvement of additional Fas-specific 
signals.   
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4. Discussion 
Negative regulation of B cell activation by cognate immune complexes plays an 
important homeostatic role in preventing B cell hyperactivity and consequent 
potential autoimmunity. Immune complex-mediated negative feedback inhibition 
results in both growth arrest and apoptosis and we now show that full activation 
of this apoptotic pathway requires the upregulation and activation of Fas death 
receptor signalling. Such apoptotic signalling is associated with caspase 8 
activity, recruitment of both transcriptional-dependent and independent p53 
apoptotic pathways and destabilisation of mitochondrial and 
endosomal/lysosomal compartments with consequent activation and interplay of 
executioner caspases and endosomal/lysosomal-derived proteases. The 
requirement for disruption of both mitochondrial- and lysosomal-integrity is 
evidenced by the finding that inhibitors of effector caspases 3 and 9 were only 
partially protective whilst those selective for the endosomal-derived proteases, 
cathepsin B and calpain, could only prevent apoptosis when used in 
combination with inhibitors of the various effector caspases.  
The precise mechanisms involved in BCR/FcγRIIB-mediated MMP and 
LMP have not yet been fully delineated but involve gene induction of the p53 
targets, Bad and Bid that presumably activate Bax to induce MMP and/or LMP, 
as well as direct destabilising effects of p53 on mitochondrial and/or lysosomal 
membranes [33, 38, 40-42]. Interestingly, p53 signalling has previously been 
shown to upregulate Fas expression both by transcriptionally-dependent [48] 
and -independent means, the latter reflecting increased trafficking of Fas from 
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intracellular stores to the cell surface [49], suggesting that it may be involved in 
BCR/FcγRIIB-coupled apoptotic signalling both upstream and downstream of 
Fas death receptor upregulation. Similarly, FasL upregulation and increased 
death receptor signalling has been reported to be a result of inhibition of Akt in 
Jurkat cells [50] and this may also be the case during FcγRIIB-mediated 
negative feedback inhibition, in which the B cells exhibit reduced Akt signalling 
[10, 51]. Thus, in addition to promoting the activities of the pro-apoptotic Bcl-2 
family members, Bad and Bid, BCR/FcγRIIB-mediated suppression of Akt 
activity and induction of p53 signalling may act to expedite apoptosis of B cells 
undergoing negative feedback inhibition by immune complexes by upregulating 
Fas and FasL to facilitate fratricide/suicide of such B cells.  
MMP dissipation and LMP are both reported to be promoted by the pore-
forming Bcl-2 family member, Bax and its activator tBid whilst dephosphorylated 
Bad has, to date, been implicated only in transducing mitochondrial disruption 
[33, 52, 53]. Perhaps consistent with this, the pan-caspase inhibitor Q-VD-OPhe, 
which blocked Bid cleavage, could only partially protect against MMP whilst it 
could fully prevent LMP and apoptosis. It was at first sight perhaps surprising that 
caspase 8 did not mediate Bid cleavage as reported for Fas-mediated apoptosis 
of other cell types [34], but this finding was corroborated by the lack of protection 
against MMP and LMP afforded by the caspase 8 inhibitor, despite its ability to 
suppress apoptosis. Moreover, these data reflect earlier studies suggesting that 
death receptor-mediated caspase 8 signalling directly activates caspase 3 and 
other effector molecules in lymphoid cells [34, 35]. The identity of the caspase(s) 
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involved in Bid cleavage remains unclear, as none of the inhibitors of caspase 2, 
3, 8 or 9 were alone able to block either MMP or LMP. However, this lack of 
effect of individual caspases may simply reflect the complex interplay of 
caspases, cathepsins and calpains resulting from MMP disruption and LMP 
required for BCR/FcγRIIB-mediated apoptosis as cathepsin-mediated tBid 
formation and consequent mitochondrial disruption has previously been shown to 
occur downstream of caspase-dependent LMP in other systems [54, 55]. Indeed, 
B cells appear to employ different effector mechanisms of apoptosis as tolerance 
checkpoints at distinct stages of development as we have previously shown that 
whilst BCR-mediated apoptosis of WEHI-231 immature B cells is dependent on 
cathepsin B, it can occur independently of caspase activation [21, 56]. By 
contrast, BCR-mediated apoptosis of PNA+ GC B cells can be partially blocked 
by caspase inhibitors [56] and consistent with the later finding, apoptosis of 
human GC B cells requires the activation of both caspase and cathepsin 
activities, the cathepsin activity being downstream of caspase 3 and responsible 
for exonuclease activity and execution of apoptosis [57].  
Nuclear export and targeting of p53 to the mitochondria and lysosomes 
for direct apoptotic signalling has been shown to occur by several mechanisms. 
Firstly, nuclear export of p53 (and its related family members, p63 and p73) and 
translocation to the mitochondria has been shown to reflect cleavage by a 
variety of caspases (caspases 3, 6, 7 and 8), generating truncated forms, some 
of which lack the nuclear localisation signal and exhibit enhanced apoptotic 
activity [58-60]. Nucleocytoplasmic shuttling of p53 also appears to be regulated 
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by several of the other apoptotic signals [42, 61, 62] induced by BCR/FcγRIIB 
co-ligation.  Thus, whilst Bid and p53 have been reported to associate in order to 
facilitate nuclear export and induction of the mitochondrial pathway of apoptosis 
[38, 39], dephosphorylated Bad can also complex with, and target p53 to the 
mitochondria [40]. Similarly, following phosphorylation on Ser15, p53 is recruited 
to, and interacts with, LAPF at the lysosomes where it acts to destabilise 
lysosomal membranes [41, 63]. Collectively, the induction of caspase-, hypo-
phosphorylated Bad, Bid and p53pSer15 signals suggests that BcR/FcγRIIB–
signalling may employ both Bid/Bad-dependent and independent mechanisms of 
trafficking p53 to the mitochondria and lysosomes and consequent induction of 
MMP and LMP.    
FcγRIIB signalling is important, not only in regulating B cell activity, but 
also in maintaining B cell tolerance at late checkpoints of peripheral 
development, particularly those involving class-switched B cells and antibody-
producing plasmablast/plasma cells. Thus, it has been proposed that the 
simultaneous activatory (Ag/BCR) and inhibitory (IgG/FcγRIIB) signals 
generated by immune complexes tethered to follicular dendritic cells in GC sets 
an activation threshold that ensures that only high affinity (non-autoreactive) B 
cells are capable of developing to antibody-producing B cells (reviewed in [64, 
65]). Given the mitochondrial and lysosomal-components of FcγRIIB-mediated 
apoptosis demonstrated here, it is perhaps pertinent to the tolerance-
maintaining function of FcγRIIB that it has previously been reported that 
apoptosis of GC B cells requires lysosomal destabilisation [27] and that Fas 
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signalling is involved in the deletion of low affinity BCR-expressing B cells in GC 
[66].  Consistent with this idea of FcγRIIB setting a tolerance-induction threshold, 
FcγRIIB-deficient mice on C57BL/6 backgrounds produce increased levels of 
antibodies of lower affinity and show increased susceptibility to induced and 
spontaneous autoimmune pathologies such as arthritis [67] and lupus-like 
glomerulonephritis [68]. Likewise, promoter and allelic polymorphisms resulting 
in low expression and/or functionality of FcγRIIB are associated with 
development of SLE in humans [64, 65]. Moreover, B cells from autoimmune 
prone-mice, including MRL mice, show reduced FcγRIIB expression and 
functionality on GC B cells and plasma cells [69-71] and reflecting this, retroviral 
transfer of FcγRIIB has been shown to restore tolerance in NZM2410 and BXSB 
mice [72]. Thus, although we showed comparable levels of the BCR and 
FcγRIIB in naïve, quiescent B cells from BALB/c and MRL/Lpr mice, we  
therefore additionally compared apoptosis resulting from co-ligation of the BCR 
and FcγRIIB in B cells from MRL/MpJ-Faslpr mice relative to that observed in the 
parental MRL/MpJ strain specifically to focus on the role of Fas rather than 
FcγRIIB levels: that immune complex-induced apoptosis of B cells is partially 
mediated via Fas death receptor signalling may therefore go some way to 
explaining development of the severe autoimmune glomerulonephritis in 
FcγRIIB-deficient mice as this is reminiscent of the lupus-like pathology exhibited 
by the MRL/MpJ-Faslpr mouse.  
The Fas-specific apoptotic signals that are defective in MRL/Lpr B cells 
are not clear but are unlikely to impact on LMP and MMP as Fas upregulation is 
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only apparent some 20-48 h post crosslinking of the BCR with FcγRIIB, whilst 
significant LMP and MMP can be detected within 3-6 h respectively. Indeed, our 
data clearly show that LMP and MMP is essentially intact in the absence of Fas 
signalling. Moreover, whilst inhibition of the Fas effector, caspase-8 suppresses 
BCR/FcγRIIB-mediated apoptosis, it does not block either LMP or MMP and 
consistent with this, we also find that the caspase 8 inhibitor does not suppress 
the generation of tBID required for Bak/Bax-mediated MMP.  Rather, our 
preliminary data (unpublished results) suggest that BCR/FcγRIIB signalling 
stimulates AMPK activation to phosphorylate p53 on Ser15, resulting in p53 
stabilisation and consequent induction of Fas expression and caspase 8 
activation [73, 74]. Similar lag times between such p53 stabilisation (maximal 1-
4 h) and induction of Fas and caspase 8 activation (maximal >20 h) have 
previously been reported [74] in models of DNA damage–induced apoptosis and 
are proposed to reflect cell cycle arrest resulting from transactivation of 
p21waf1. This lag period reflects the time course of BCR/FcγRIIB-mediated, 
p53-dependent upregulation of Fas expression that occurs subsequent to 
establishment of LMP and MMP.  Collectively, therefore, these data suggest that 
Fas/FasL upregulation may be a marker of an absolute “point of no return” and 
that such late Fas-mediated apoptotic signals reflect direct caspase 8-
dependent activation of caspase 3 and associated effector pathways that 
complement the early mitochondrial/lysosomal pathways to expedite rapid and 
full execution of apoptosis.	  Thus, dysfunction of such Fas-dependent FcγRIIB-
mediated negative feedback and tolerance-inducing signals in the MRL/MpJ-
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Faslpr mouse could provide an additional mechanism to explain the chronic 
activation of autoreactive B cells and consequent extremely high levels of 
autoantibodies characteristic of the lupus-like pathology of this model [75, 76].  
Interestingly, FcγRIIB deficiency is also associated with an increased 
resistance in naïve mice to infections such as Streptococcus pneumoniae, 
Staphylococcus aureus and Mycobacterium tuberculosis, although challenge of 
immunised FcγRIIB-deficient mice with S. pneumoniae resulted in higher 
mortality due to septic shock [65].  FcγRIIB signalling therefore appears to be 
essential not only for maintaining B cell tolerance and homeostasis but also for 
promoting an optimal balance in fighting infection without incurring septic shock. 
It has been proposed that modulation of FcγRIIB levels/signalling might be a 
promising therapeutic strategy for combating systemic autoimmune disorders 
such as SLE [64, 65] but these interesting findings relating to the role of FcγRIIB 
in regulating responses to infection suggest that more selective targeting and 
consequent upregulation of Fas-dependent apoptotic pathways may provide the 
starting point for safer therapies.  
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6. Figure Captions 
Figure 1. Immune complex-mediated disruption of MMP and consequent 
apoptosis is caspase-dependent.  In all panels, B cells were stimulated as 
indicated with either medium, IL-4 (10 ng/ml) and/or 50 µg/ml F(ab’)2 anti-mouse 
IgM  (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in combination with 75 µg/ml 
anti-mouse IgG+IgM (BCR/FcγRIIB-X). Where indicated, cells were pre-treated 
with the pan-caspase inhibitor Q-VD-OPhe (X+Q, 10 µM) for 1 h. (Ai) CFSE-
labelled B cells were stimulated for 72 h and cell proliferation tracked by the 
dilution of CFSE fluorescence. Percentages of cells within each generation were 
plotted for each condition. Data are representative of three independent 
experiments. (Aii) DNA synthesis after 48 h of stimulation was assessed by the 
[3H] thymidine uptake assay and data are shown as counts per minute (cpm) ± 
standard deviation (SD) of triplicate values from a single experiment 
representative of at least five independent experiments where p<0.001 (BCR 
stimulated cells compared to the cells which received BCR/FcγRIIB-X co-
ligation). (B) DNA content was determined by FACS analysis of PI staining. The 
extent of apoptosis is presented as the percentage of cells containing subdiploid 
DNA in the total cell population. (i) Representative PI profile obtained after 
FACS analysis. (ii) Data are presented as mean percentage of all cells in each 
cell cycle stage (± SD of triplicate values, p<0.001 for BCR/FcγRIIB-X in 
comparison with X+Q-VD-Ophe and IL-4) and are representative of at least five 
experiments. (C) MMP was assessed after 24 h of stimulation by FACS analysis 
of DiOC6 staining (i) Representative DIOC6 profile after FACS analysis. (ii) Data 
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are presented as mean percentage of cells with low MMP (low DIOC6 staining) 
(± SD of triplicate values) and are representative of at least three experiments, 
p<0.001 in comparison with BCR/FcγRIIB-X. (D) Time course of MMP 
dissipation shown as mean percentage of cells with low MMP ± SD of triplicate 
values. Data are representative of three experiments, p<0.001 for BCR/FcγRIIB-
X in comparison with X+Q-VD-OPhe (E) Mitochondrial and cytosolic extracts 
were prepared following stimulation for 48 h and assessed for the cytochrome C 
content by ELISA. Results are displayed as a ratio of cytochrome C levels in the 
cytosol as compared to the mitochondria.  
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Figure 2: Co-ligation of the BCR and FcγRIIB activates caspases. B cells 
were stimulated with either IL-4 (10 ng/ml) or 50 µg/ml F(ab’)2 anti-mouse IgM in 
combination with 75 µg/ml anti-mouse IgG+IgM (BCR/FcγRIIB-X). Where 
indicated, cells were pre-treated with the pan-caspase inhibitor Q-VD-OPhe 
(X+Q, 10 µM) for 1 h. Caspase 3 (A), 8 (B) and 9 (C) activation was determined 
by FACS analysis of the appropriate FITC-conjugated caspase inhibitor. 
Representative histogram plots of the indicated FITC-inhibitor staining after 16 h 
of stimulation and the time courses of activation of the relevant caspases are 
shown where data are presented as percentage of cells that have caspase 
activity ± SD of triplicate values from a single experiment, representative of three 
independent experiments (p<0.001 BCR/FcγRIIB-X compared to either IL-4 or 
X+Q-VD-Ophe stimulated cells). 
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Figure 3: Caspase 8 inhibition blocks apoptosis induced by co-ligation of 
BCR with FcγRIIB. B cells were stimulated with either medium, IL-4 (10 ng/ml) 
or 50 µg/ml F(ab’)2 anti-mouse IgM  (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in 
combination with 75 µg/ml anti-mouse IgG+IgM (BCR/FcγRIIB-X). In addition, 
cells were pre-treated with the pan-caspase inhibitor Q-VD-OPhe (10 µM) or 
selective Caspase 2, 3, 8, or 9 inhibitors (10 µM) for 1 h prior to stimulation, as 
indicated. (A) Apoptosis at 24 h was assessed by PI staining and data presented 
as percentage of cells containing subdiploid DNA in total cell population. Data 
are presented as the mean of the mean values from three independent 
experiments ± SEM (p<0.001, compared to BCR/FcγRIIB-X). (B) MMP at 24 h 
was determined by FACS analysis of DIOC6 staining and data are presented as 
the mean percentage of cells with low MMP ± SD of triplicate values from a 
single experiment representative of at least three independent experiments. 
(p<0.001, for X+Q or IL-4 stimulated cells compared to the cells stimulated 
through BCR/FcγRIIB-X). (C) DNA synthesis was assessed after 48 h of 
stimulation data are shown as mean cpm ± SD of triplicate values from a single 
experiment representative of two independent experiments (p<0.001, compared 
to the cells stimulated through BCR).  
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Figure 4. BCR/FcγRIIB co-ligation induces LMP. B cells were stimulated in 
the presence of either IL-4 (10ng/ml) or 50 µg/ml F(ab’)2 anti-mouse IgM in 
combination with 75 µg/ml anti-mouse IgG+IgM (BCR/FcγRIIB-X) for 16 h or the 
indicated time course (panels A, C & D). B cells were stimulated with IL-4 (10 
ng/ml) or 50 µg/ml B7.6 anti-IgM plus 50 µg/ml 2.4G2 anti-FcγRIIB followed by 
75 µg/ml of donkey anti-rat IgG to crosslink B7.6 and 2.4G2 leading to coligation 
of BCR and FcγRIIB (panel B). Where indicated, cells were also pre-treated with 
pan-caspase inhibitor Q-VD-OPhe (10 µM) or the selective caspase (caspase 8 
z-IETD-FMK 10 µM and caspase 9 z-LEHD-FMK 10 µM) or endosomal (EST 10 
µM /Calpain inhibitor 10 µM) or lysosomal (E64d 10 µM + pepstatin A 10 µg/ml) 
inhibitors either alone or in combination for 1 h prior to stimulation. (A) 
Representative plots showing gating strategy for enumerating the percentage of 
‘pale’ cells indicative of LMP as assessed by FACS analysis following staining 
with either acridine orange (AO) or Lysotracker Red DND99. In addition the time 
course of LMP is shown where data are presented as mean percentage ± SD of 
‘pale’ cells (stained with Lysotracker Red DND99) at each time point from a 
single experiment representative of at least three independent experiments 
(p<0.001 BCR/FcγRIIB-X compared to either IL-4 or X+Q-VD-Ophe stimulated 
cells). (B) Cytosolic and membrane/ organelle fractions were prepared following 
stimulation for 16 h and analysed by Western blotting for Cathepsin B (C-19) 
expression. Fractions were probed for LAMP-1 (lysosomal maker) and GAPDH 
(cytosol marker) as quality control for fraction preparation. Data are 
representative of three independent experiments. (C) LMP was assessed by the 
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% pale cells (stained with Lysotracker Red DND99) after 16 h. Data are mean 
values ± SD of triplicate values from a single experiment representative of at 
least three independent experiments (p<0.001, compared to BCR/FcγRIIB-X). 
(D) Apoptosis (sub-diploid staining) was assessed by FACS analysis of PI 
staining of DNA content where data are mean ± SD of triplicate values from a 
single experiment representative of 3 independent experiments (p<0.001, for 
X+C9I compared to X+C9I+EST+Calp.Inh).  
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Figure 5. Co-ligation of BCR/FcγRIIB induces a complex interplay of p53, 
Bid and Bad signals.  B cells were stimulated with medium or IL-4 (10 ng/ml) or 
50 µg/ml B7.6 anti-IgM (BCR) or 50 µg/ml B7.6 anti-IgM plus 50 µg/ml 2.4G2 
anti-FcγRIIB followed by 75 µg/ml of donkey anti-rat IgG to crosslink B7.6 and 
2.4G2 leading to coligation of BCR and FcγRIIB (panels A & C). B cells were 
stimulated with either medium, IL-4 (10 ng/ml) or 50 µg/ml F(ab’)2 anti-mouse 
IgM (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in combination with 75 µg/ml anti-
mouse IgG+IgM (BCR/FcγRIIB-X) in panels B and D. Where indicated, cells 
were pre-treated with either the caspase 8 (C8I, z-IETD-FMK 10µm) or pan-
caspase (Q-VD-OPhe, 10µM) inhibitor for 1 h. (A) WCL were prepared after 24 
h stimulation and analysed by Western blotting for p53 expression. Probing with 
β-actin was used as loading control. Data are representative of at least three 
independent experiments. (B) Nuclear extracts were prepared at 48 h post 
stimulation for assay of p53 transactivation activity by a modified ELISA 
(TransAM) method. Data are displayed as the mean level of p53 activity ± SD 
where n=3 from a single experiment representative of 3 independent 
experiments. WCL were prepared 24 h post stimulation and caspase-8 and Bid 
cleavage (C) were assessed by Western blotting. Levels of housekeeping genes 
β-actin and GAPDH were used as loading controls (C). Data are representative 
of three independent experiments. (D) Levels of Bad expression were 
determined by Western Blotting (24 h; i) or the FACE ELISA method (48 h; ii) 
where data are displayed as mean Bad signal ± SD of triplicate values of a 
single experiment representative of three independent experiments. 
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Fig. 6. Coligation of BCR/FcγRIIB induces nuclear export of p53 and Ser15 
phosphorylation. B cells were stimulated with either medium, IL-4 (10 ng/ml) or 
50 µg/ml F(ab’)2 anti-mouse IgM  (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in 
combination with 75 µg/ml anti-mouse IgG+IgM (BCR/FcγRIIB-X) in panels A 
and C. B cells were stimulated with IL-4 (10 ng/ml) or 50 µg/ml B7.6 anti-IgM 
plus 50 µg/ml 2.4G2 anti-FcγRIIB followed by 75 µg/ml of donkey anti-rat IgG to 
crosslink B7.6 and 2.4G2 leading to coligation of BCR and FcγRIIB in panel B. 
Where indicated, cells were pre-treated with the phosphatase (microcystin 1 µM) 
inhibitor for 1 h. (Ai) pBad/Bad levels were determined using the FACE ELISA 
method. The data are displayed as a ratio of the mean phospho-Bad to mean 
Bad signal and are from a single experiment representative of two independent 
experiments. (Aii) Akt activation was assessed by the ratio of pAkt/Akt 
expression determined using the FACE ELISA method. Cells treated with 
microcystin assessed the cumulative AKT phosphorylation over 48 h whereas 
cells without microcystin were used to assess the phospho-AKT levels at 48 h. 
The data are displayed as a ratio of the mean pAKT to mean AKT signal and are 
from a single experiment representative of four independent experiments. (B) 
Cytosolic and nuclear fractions were prepared 16 h post-stimulation and 
analysed by Western Blot for p53 expression. Fractions were probed for HDAC-
1 (nuclear maker) and GAPDH (cytosolic marker) expression for a quality control 
for fraction preparation. Data are representative of at least three independent 
experiments. (C) p53-containing immune complexes were subjected to Western 
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Blot analysis with an anti-phospho-p53 (Ser15) antibody and then stripped and 
re-probed with an anti-p53 antibody.  
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Figure 7. Co-ligation of the BCR with FcγRIIB upregulates Fas expression. 
B cells were stimulated with either medium, IL-4 (10 ng/ml) or 50 µg/ml F(ab’)2 
anti-mouse IgM  (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in combination with 
75 µg/ml anti-mouse IgG+IgM (BCR/FcγRIIB-X) in panels A & Biii. B cells were 
stimulated with IL-4 (10 ng/ml) or 50 µg/ml B7.6 anti-IgM (BCR) or 50 µg/ml B7.6 
anti-IgM plus 50 µg/ml 2.4G2 anti-FcγRIIB followed by 75 µg/ml of donkey anti-
rat IgG to crosslink the B7.6 and 2.4G2 leading to coligation of BCR and FcγRIIB 
(Bi & ii ). Where indicated, cells were pretreated with a caspase 8 inhibitor (C8I, 
z-IETD-FMK 10 µM). (A) Representative plots of Fas surface expression 
detected on cells 24h after stimulation with (i) IL-4 or BCR/FcγRIIB co-ligation, 
(ii) BCR/FcγRIIB alone or in combination with caspase 8 inhibitor. Data shown 
are representative of at least three independent experiments. (B) WCL were 
prepared 24 h post-stimulation and levels of Fas and FasL assessed by Western 
blot analysis (Bi). Levels of the housekeeping gene β-actin were used as a 
loading control. (Bii) The intensities of bands representing FasL expression 
between different stimulation conditions were compared using ImageJ software.  
Data are presented as a ratio of the densitometric values of bands containing 
FasL and β-actin for each stimulation condition. Data are representative of at 
least three experiments. (Biii) mRNA levels of FasL expression were detected by 
TaqMan® quantitative RT-PCR using GAPDH as endogenous control. Data is 
shown as mean % expression relative to GAPDH ± SEM of triplicate values.  
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Figure 8. Fas signalling contributes to apoptosis induced by co-ligation of 
BCR/FcγRIIB. B cells were cultured in the presence of 50 µg/ml F(ab’)2 anti-
mouse IgM or 50 µg/ml F(ab’)2 anti-mouse IgM in combination with 75 µg/ml anti-
mouse IgG+IgM. Where indicated cells were treated with 5 or 10 µg/ml of anti-
FasL blocking antibody or as a control, the equivalent concentration of Armenian 
hamster IgG. (A) DNA content was assessed by FACS analysis of PI staining, 
and apoptosis was determined as percentage of cells containing subdiploid DNA 
content within the total cell population for each treatment condition. Data are 
representative of two independent experiments. (B & C) Resting thymocytes (T; 
B) and B cells, either resting (B0; B & C) or following co-ligation of the 
BCR/FcγRIIB for 44 h (B44; B) from BALB/c or MRL/MpJ-Faslpr (MRL/Lpr) mice 
were analysed for Fas (black line; B) and BCR (IgM, black line, isotype control, 
grey shading; C) surface expression by FACS analysis. Analysis of Fas staining 
relative to an appropriate isotype control (results not show) or following “Fas 
blocking” with unlabelled anti-Fas antibody (grey shading), revealed that the low 
level of Fas staining observed in naive B cells, but not thymocytes, from BALB/c 
and MRL/Lpr mice was non-specific. Data are representative of at least three 
independent experiments. (D) Resting thymocytes (T) and B cells, either resting 
(B0) or following co-ligation of the BCR/FcγRIIB for 24 (B24) or 40 h (B40) from 
BALB/c or MRL/MpJ-Faslpr (MRL/Lpr) mice were analysed for Fas, FcγRIIB 
(CD32) and BCR (IgM heavy chain) by Western Blot analysis, with GAPDH 
expression as a loading control. Data are representative of at least three 
independent experiments. 
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Figure 9. Apoptosis induced by co-ligation of BCR/FcγRIIB is reduced in 
MRL/Lpr B cells. B cells were stimulated in the presence of IL-4 (10 ng/ml) or 
50 µg/ml F(ab’)2 anti-mouse IgM or 50 µg/ml F(ab’)2 anti-mouse IgM in 
combination with 75 µg/ml anti-mouse IgG+IgM. (A) DNA content was assessed 
by FACS analysis of PI staining and the extent of apoptosis was determined as 
percentage of cells containing subdiploid DNA content within the total cell 
population for each treatment condition for B cells from (i) MRL/MpJ and (ii) 
MRL/MpJ-Faslpr (MRL/Lpr) mice. (iii) Data represent the relative levels of 
subdiploid cells induced by BCR/FcγRIIB coligation (normalised against values 
from BCR-stimulated cells) in MRL/MpJ-Faslpr (MRL/Lpr ) versus MRL/MpJ B 
cells and are expressed as the mean values ± SEM relative to the normalised 
levels found in the MRL/MpJ cells and are pooled from 4 experiments with B 
cells from MRL/MpJ-Faslpr (MRL/Lpr) mice. (B) DNA synthesis at 48 h was 
assessed by the [3H]thymidine assay of B cells from (i) MRL/MpJ and (ii) 
MRL/MpJ-Faslpr (MRL/Lpr) mice. (iii) Data (normalised against values from 
BCR-stimulated cells) represent the mean ± SEM percentage of BCR responses 
obtained by coligation of FcγRIIB pooled from 4 experiments using B cells from 
BALB/c, MRL/MpJ and MRL/MpJ-Faslpr (MRL/Lpr) mice (** p<0.01, *p<0.05). 
(C) LMP (i), MMP dissipation (ii) and DNA content (iii) were measured at the 
indicated time and data presented as means ± SD of triplicate values from a 
single experiment representative of two independent experiments. (p<0.001 for 
BCR/FcγRIIB-X stimulated BALB/c cells in comparison to MRL/MpJ-Faslpr 
(MRL/Lpr) mice).  
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